- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02060903
A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized, double-blind, multicenter, vehicle-controlled, parallel-group study in subjects with active head lice infestation. The study was designed to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to scalp and hair for 10 minutes at home.
Approximately 106 index subjects with their household members were enrolled into the study. A total of approximately 318 subjects were enrolled, assuming an average of 3 members per household participating in the study.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Dinuba, California, United States, 93618
- Universal Biopharma Reserach INC
-
Los Angeles, California, United States, 90036
- Axis Clinical Trials
-
-
Florida
-
West Palm Beach, Florida, United States, 33407
- LSRN Reserach
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Impact Clinical Trials
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Haber Dermatology
-
-
Tennessee
-
McKenzie, Tennessee, United States, 38201
- McKenzie Medical Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Radiant reserach Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, aged six months of age or older.
- Is in good general health based on medical history.
- Has active head lice infestation at Screening as determined by a trained evaluator with the exception of the male head of household who may self-assess as being lice-free. Active head lice infestation is defined as at least three live lice for the index subject and at least one live louse for the other household members.
- The subject and/or their caregiver is physically able and willing to apply the Investigational Product at home.
- Belongs to a household with an eligible index subject with active head lice infestation.
- Agrees to an examination for head lice and to all visits and procedures throughout the study.
- Has signed an informed consent and/or assent form.
Exclusion Criteria:
- Had treatment (over-the-counter ), home remedy or prescription medication) for head lice within 14 days prior to Day 0.
- Intends to use any other form of lice treatment from Day 0 through the Day 14 visit, unless provided as rescue therapy to this Protocol.
- Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as rescue therapy to this Protocol.
- Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling from Day 0 through the Day 14 visit.
- Has a household member(s) who is infested with lice but is not willing or not eligible for enrollment.
- Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.
- Has visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or Sponsor, will interfere with safety and/or efficacy evaluations.
- Has eczema or atopic dermatitis of skin/scalp.
- Has had a prior reaction to Nix® or products containing permethrin.
- Receiving systemic or topical medication, which in the opinion of the Investigator, may compromise the integrity of the safety and/or efficacy assessments.
- Has received an investigational agent within 30 days prior to Day 0.
- Does not have a known household affiliation with the household members (i.e., does not stay in one household consistently, or sleeps at one place for several nights and then at another place or location).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Abametapir Lotion 0.74% w/w
Single topical treatment administered to hair and scalp for 10 minutes.
Applied at home by a subject/caregiver.
|
Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
Other Names:
|
PLACEBO_COMPARATOR: Vehicle Lotion
Single topical treatment administered to hair and scalp for 10 minutes.
Applied at home by a subject/caregiver.
|
Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.
Time Frame: 14 days
|
Proportion of index subjects randomized into the study who are lice free at all follow up visits through to the Day 14 visit.
The index subject of a household was the youngest person within that household with at least 3 live lice present, as assessed over a period of up to 15 minutes at the Screening Visit.
|
14 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ha03-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head Lice Infestation
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States
-
Infectopharm Arzneimittel GmbHRecruitingPediculosis Capitis | Head Lice Infestation | LiceGermany
-
Perrigo CSCIRecruitingHead Lice InfestationMauritius
-
Dr. Reddy's Laboratories LimitedCompletedHead Lice InfestationUnited States
-
Dr. Reddy's Laboratories LimitedTarget Health Inc.; AccelovanceCompleted
-
Dr. Reddy's Laboratories LimitedCompletedHead Lice InfestationAustralia
-
Alliance PharmaceuticalsSouth Florida Family Health and Research CentersRecruitingHead Lice | Lice Infestations | Pediculosis CapitisUnited States
-
Boston Scientific CorporationCompletedHead Lice | Pediculus Humanus CapitisUnited States
-
Medical Entomology CentreRiemann a/sTerminatedPediculosis | Head Louse Infestation
-
Medical Entomology CentreRiemann a/s; PN Lee Statistics and Computing LtdTerminatedPediculosis Capitis | Head Louse InfestationUnited Kingdom
Clinical Trials on Abametapir Lotion 0.74% w/w
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States
-
Dr. Reddy's Laboratories LimitedCompletedHead Lice InfestationAustralia
-
Dr. Reddy's Laboratories LimitedTKL Research, Inc.; AccelovanceCompletedHead LiceUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompletedHead Lice InfestationUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
GlaxoSmithKlineCompleted
-
Mimetica Pty LimitedUnknownAcne VulgarisUnited States
-
Mimetica Pty LimitedCompleted
-
Amytrx Therapeutics, Inc.Amarex Clinical ResearchCompletedAtopic DermatitisUnited States